Ressources numériques en sciences humaines et sociales OpenEdition Nos plateformes OpenEdition Books OpenEdition Journals Hypothèses Calenda Bibliothèques OpenEdition Freemium Suivez-nous

UK – Gilead’s CAR-T cell therapy recommended by NICE for lymphoma

Gilead Science and Kite, a Gilead company, have announced that the National Institute for Health and Care Excellence (NICE) has recommended Yescarta (axicabtagene ciloleucel) to treat certain forms of lymphoma.

Specifically, the therapy is now recommended for adult patients with diffuse large B-cell lymphoma (DLBCL) or primary mediastinal large B-cell lymphoma (PMBCL) who have already been treated with two or more systemic therapies.

The decision from NICE makes Yescarta the first chimeric antigen receptor (CAR) T-cell therapy to be recommended for routine use on the NHS.

More information on the RIS.WORLD Website.


OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (19 avril 2023). UK – Gilead’s CAR-T cell therapy recommended by NICE for lymphoma. ELSIBI. Consulté le 19 février 2026 à l’adresse https://doi.org/10.58079/o68x


Vous aimerez aussi...

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *

This site uses Akismet to reduce spam. Learn how your comment data is processed.